Specialty distributor BioCareSD is offering Tepezza and Krystexxa.
The company noted that these two additions further reinforce BioCareSD’s commitment to leading the specialty distribution industry and providing therapeutics to a wider patient population while offering best-in-class customer service and a unique distribution network that enables high-quality patient care.
Manufactured by Horizon Therapeutics, Tepezza is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of thyroid eye disease.
Krystexxa, also manufactured by Horizon Therapeutics, is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. In addition to broadening BioCareSD’s portfolio, these updates enable BioCareSD to service additional patients.
[Read more: Retailers build out their specialty offerings]
“These specialty products exemplify our focus on supporting the unmet needs of customers,” said Linda Matthews, president of BioCare. “We pride ourselves on being true partners to manufacturers, healthcare providers and distributors, and are honored to expand our specialty life-saving offerings to new patient populations.”